Following its voclosporin's phase III lupus hit Aurinia intends to launch in the US on its own, but seeks partners for other areas.
The Japanese group has seen potential in Audentes' manufacturing capabilities as well as its pipeline.
Twin setbacks for grass pollen allergy projects in development by Asit Biotech and Allergy Therapeutics expose an existential crisis.
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
With data showing superiority over glucocorticoids, Chemocentryx could have a new standard of care for vasculitis in avacopan.
Rather than nipping at Adakveo’s heels, Global Blood Therapeutics’ newly approved sickle cell drug Oxbryta might end up floundering in the Novartis product’s wake.
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
Alnylam unveils a novel pricing strategy for its second RNAi launch, which was greenlit by the US regulator with notable speed.